This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Gianfaldoni, C.
Right arrow Articles by Ruggiero, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gianfaldoni, C.
Right arrow Articles by Ruggiero, P.

 Previous Article  |  Next Article 

Infection and Immunity, July 2009, p. 2957-2961, Vol. 77, No. 7
0019-9567/09/$08.00+0     doi:10.1128/IAI.01516-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Sortase A Confers Protection against Streptococcus pneumoniae in Mice{triangledown}

Claudia Gianfaldoni,1 Silvia Maccari,1 Laura Pancotto,1 Giacomo Rossi,2 Markus Hilleringmann,1 Werner Pansegrau,1 Antonia Sinisi,1 Monica Moschioni,1 Vega Masignani,1 Rino Rappuoli,1 Giuseppe Del Giudice,1 and Paolo Ruggiero1*

Novartis Vaccines and Diagnostics s.r.l., Research Center, Siena, Italy,1 University of Camerino, Department of Veterinary Sciences, Matelica, Italy2

Received 15 December 2008/ Returned for modification 19 February 2009/ Accepted 29 April 2009

Streptococcus pneumoniae sortase A (SrtA) is a transpeptidase that is highly conserved among pneumococcal strains, whose involvement in adhesion/colonization has been reported. We found that intraperitoneal immunization with recombinant SrtA conferred to mice protection against S. pneumoniae intraperitoneal challenge and that the passive transfer of immune serum before intraperitoneal challenge was also protective. Moreover, by using the intranasal challenge model, we observed a significant reduction of bacteremia when mice were intraperitoneally immunized with SrtA, while a moderate decrease of lung infection was achieved by intranasal immunization, even though no influence on nasopharynx colonization was seen. Taken together, our results suggest that SrtA is a good candidate for inclusion in a multicomponent, protein-based, pneumococcal vaccine.

* Corresponding author. Mailing address: Novartis Vaccines and Diagnostics s.r.l., Research Center, Via Fiorentina, I-53100 Siena, Italy. Phone: 39.0577.243234. Fax: 39.0577.243564. E-mail: paolo.ruggiero{at}novartis.com

{triangledown} Published ahead of print on 11 May 2009.

Editor: A. Camilli

Infection and Immunity, July 2009, p. 2957-2961, Vol. 77, No. 7
0019-9567/09/$08.00+0     doi:10.1128/IAI.01516-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»